Author
Listed:
- Edward Henry
(University of Galway)
- Hareth Al-Janabi
(University of Birmingham)
- Werner Brouwer
(Erasmus University Rotterdam)
- John Cullinan
(University of Galway)
- Lidia Engel
(Monash University)
- Susan Griffin
(University of York)
- Claire Hulme
(University of Exeter Medical School)
- Pritaporn Kingkaew
(Ministry of Public Health)
- Andrew Lloyd
(Acaster Lloyd Consulting Ltd)
- Nalin Payakachat
(University of Arkansas for Medical Sciences (UAMS))
- Becky Pennington
(University of Sheffield)
- Luz María Peña-Longobardo
(University of Castilla-La Mancha)
- Lisa A. Prosser
(University of Michigan)
- Koonal Shah
(National Institute for Health and Care Excellence)
- Wendy J. Ungar
(The Hospital for Sick Children Research Institute/University of Toronto)
- Thomas Wilkinson
(University of Cape Town)
- Eve Wittenberg
(Harvard University)
Abstract
Background Omission of family and caregiver health spillovers from the economic evaluation of healthcare interventions remains common practice. When reported, a high degree of methodological inconsistency in incorporating spillovers has been observed. Aim To promote emerging good practice, this paper from the Spillovers in Health Economic Evaluation and Research (SHEER) task force aims to provide guidance on the incorporation of family and caregiver health spillovers in cost-effectiveness and cost-utility analysis. SHEER also seeks to inform the basis for a spillover research agenda and future practice. Methods A modified nominal group technique was used to reach consensus on a set of recommendations, representative of the views of participating subject-matter experts. Through the structured discussions of the group, as well as on the basis of evidence identified during a review process, recommendations were proposed and voted upon, with voting being held over two rounds. Results This report describes 11 consensus recommendations for emerging good practice. SHEER advocates for the incorporation of health spillovers into analyses conducted from a healthcare/health payer perspective, and more generally inclusive perspectives such as a societal perspective. Where possible, spillovers related to displaced/foregone activities should be considered, as should the distributional consequences of inclusion. Time horizons ought to be sufficient to capture all relevant impacts. Currently, the collection of primary spillover data is preferred and clear justification should be provided when using secondary data. Transparency and consistency when reporting on the incorporation of health spillovers are crucial. In addition, given that the evidence base relating to health spillovers remains limited and requires much development, 12 avenues for future research are proposed. Conclusions Consideration of health spillovers in economic evaluations has been called for by researchers and policymakers alike. Accordingly, it is hoped that the consensus recommendations of SHEER will motivate more widespread incorporation of health spillovers into analyses. The developing nature of spillover research necessitates that this guidance be viewed as an initial roadmap, rather than a strict checklist. Moreover, there is a need for balance between consistency in approach, where valuable in a decision making context, and variation in application, to reflect differing decision maker perspectives and to support innovation.
Suggested Citation
Edward Henry & Hareth Al-Janabi & Werner Brouwer & John Cullinan & Lidia Engel & Susan Griffin & Claire Hulme & Pritaporn Kingkaew & Andrew Lloyd & Nalin Payakachat & Becky Pennington & Luz María Peña, 2024.
"Recommendations for Emerging Good Practice and Future Research in Relation to Family and Caregiver Health Spillovers in Health Economic Evaluations: A Report of the SHEER Task Force,"
PharmacoEconomics, Springer, vol. 42(3), pages 343-362, March.
Handle:
RePEc:spr:pharme:v:42:y:2024:i:3:d:10.1007_s40273-023-01321-3
DOI: 10.1007/s40273-023-01321-3
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:42:y:2024:i:3:d:10.1007_s40273-023-01321-3. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.